Portal CEO on Lilly Deal for Cancer Biotech CrossBridge
The Big Market Report Take
Portal Innovations CEO John Flavin provides a look into the 2026 biotech M&A pipeline and breaks down Eli Lilly’s purported acquisition of CrossBridge Bio for up to $300 million, bolstering its oncology segment. He talks with Katie Greifeld and Romaine Bostick on “The Close.” (Source: Bloomberg)
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- VFLO: Free Cash Flow + Growth Is A Winning FormulaSeeking Alpha26m ago
- Koninklijke KPN N.V. (KKPNY) Shareholder/Analyst Call TranscriptSeeking Alpha27m ago
- AMD: Why It's A 'Hold' At Current LevelsSeeking Alpha30m ago
- ECB Officials Are Leaning Toward April Rate HoldBloomberg Markets31m ago